• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket

    9/13/22 6:15:07 AM ET
    $ACRX
    $AREB
    $CDAK
    $CMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Plastic Products
    Industrials
    Get the next $ACRX alert in real time by email

    Gainers

    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average price of $2.03 - $2.07.
    • Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares rose 35.6% to $0.9906 in pre-market trading after the FDA granted Syros Pharmaceuticals Orphan Drug Designation for the treatment of pancreatic cancer.
    • Zovio Inc (NASDAQ:ZVO) rose 30.3% to $0.3074 in pre-market trading after declining over 5% on Monday.
    • iBio, Inc. (NYSE:IBIO) rose 18.1% to $0.32 in pre-market trading after declining over 4% on Monday.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) rose 17.3% to $0.7798 in pre-market trading after surging around 15% on Monday.
    • SeaChange International, Inc. (NASDAQ:SEAC) shares rose 14.5% to $0.55 in pre-market trading after reporting strong Q2 sales.
    • The Very Good Food Company Inc. (NASDAQ:VGFC) rose 13.1% to $0.1899 in pre-market trading after declining around 6% on Monday. The Very Good Food Company, last week, announced a review of strategic alternatives.
    • Tyme Technologies, Inc. (NASDAQ:TYME) rose 12.7% to $0.29 in pre-market trading after gaining around 4% on Monday.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) rose 11.9% to $3.20 in pre-market trading after jumping around 28% on Monday.
    • Planet Labs PBC (NYSE:PL) rose 11.5% to $6.05 in pre-market trading after the company reported better-than-expected Q2 results and raised guidance.
    • AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) rose 9.3% to $0.2747 in pre-market trading after dropping around 10% on Monday.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) rose 7.8% to $43.32 in pre-market trading amid post-IPO volatility after the stock began trading in late August.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) rose 7.7% to $1.54 in pre-market trading after gaining over 5% on Monday.
    • Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) rose 7% to $16.21 in pre-market trading. S&P Dow Jones Indices said Catalyst Pharmaceuticals will replace Mantech International Corp. in S&P Smallcap 600 on September 15.


    Don’t forget to check out our premarket coverage here .

    Losers

    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) fell 25.3% to $12.46 in pre-market trading. NeuroBo Pharmaceuticals shares jumped 101% on Monday after the company announced a 1-for-30 reverse stock split.
    • Rent the Runway, Inc. (NASDAQ:RENT) shares fell 22.9% to $3.80 in pre-market trading after the company reported issued Q3 guidance below estimates and announced a workforce reduction of 24% of corporate employees. Credit Suisse downgraded the stock from Outperform to Neutral and lowered the price target from $7 to $4.
    • Cardiff Oncology, Inc. (NASDAQ:CRDF) shares fell 19.3% to $2.59 in pre-market trading as the company announced plans for a randomized trial, durability of responses in ongoing Phase 1b/2 trial in metastatic colorectal cancer.
    • Tandy Leather Factory, Inc. (NASDAQ:TLF) fell 14.5% to $4.01 in pre-market trading.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) fell 14.4% to $1.43 in pre-market trading after the company priced 13.33 million share offering plus accompanying warrants at combined price of $1.50 per share plus warrant.
    • InMed Pharmaceuticals Inc. (NASDAQ:INM) fell 12.6% to $16.40 in pre-market trading. InMed Pharmaceuticals shares surged 70% on Monday after the company announced a $6 million private placement priced at $8.68 per share.
    • PolyPid Ltd. (NASDAQ:PYPD) fell 11.1% to $1.52 in pre-market trading after jumping 58% on Monday. The company earlier announced it will present Phase 2 D-PLEX₁₀₀ data at the European Society for Coloproctology Scientific Conference next week.
    • ShiftPixy, Inc. (NASDAQ:PIXY) shares fell 10.9% to $24.30 in pre-market trading. ShiftPixy shares dropped over 20% on Monday amid profit taking after the stock surged last week following the company's announcement it plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) fell 10.4% to $5.11 in pre-market trading after gaining 8% on Monday.
    • Kiromic BioPharma, Inc. (NASDAQ:KRBP) fell 8.5% to $0.3475 in pre-market trading after gaining 7% on Monday.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) fell 7.4% to $26.00 in pre-market trading. Revance Therapeutics priced upsized 8 million share public offering of common stock at $25 per share.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) shares fell 4.5% to $27.51 in pre-market trading. Relay Therapeutics priced 11.32 million share public offering of common stock at $26.50 per share.
    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $AREB
    $CDAK
    $CMRA

    CompanyDatePrice TargetRatingAnalyst
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    Relay Therapeutics Inc.
    $RLAY
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Planet Labs PBC
    $PL
    12/12/2025$19.00Buy
    Citigroup
    Relay Therapeutics Inc.
    $RLAY
    12/12/2025$13.00Equal Weight → Overweight
    Wells Fargo
    Terns Pharmaceuticals Inc.
    $TERN
    11/4/2025$20.00Neutral → Buy
    H.C. Wainwright
    Terns Pharmaceuticals Inc.
    $TERN
    11/3/2025Mkt Perform → Outperform
    William Blair
    iBio Inc.
    $IBIO
    10/21/2025$5.00Outperform
    Oppenheimer
    More analyst ratings

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Gary B bought $313 worth of shares (20 units at $15.66) and sold $254 worth of shares (20 units at $12.69) (SEC Form 4)

    4 - Planet Labs PBC (0001836833) (Issuer)

    2/3/26 6:35:28 PM ET
    $PL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Director Pace Gary W bought $710,500 worth of shares (290,000 units at $2.45), increasing direct ownership by 26% to 1,330,676 units (SEC Form 4)

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    7/31/25 4:05:05 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Gengos Andrew bought $39,283 worth of shares (10,000 units at $3.93), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

    6/30/25 5:38:10 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:

    8/14/23 4:38:56 AM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:

    9/8/22 1:11:06 PM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AMERICAN REBEL HOLIDNGS, INC. (NASDAQ: AREB; AREBW) ANNOUNCES 1-FOR-100 REVERSE STOCK SPLIT OF ITS COMMON STOCK AND PUBLICLY TRADED WARRANTS WITH ROUND LOT STOCKHOLDER PROTECTION TO BE EFFECTIVE ON MARCH 23, 2026

    Nashville, TN, March 19, 2026 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ:AREB) — America's Patriotic Brand (the "Company"), today announced that it will effect a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), and publicly traded warrants, par value $0.001 per share (the "Warrants"), at a ratio of 1-for-100, to be effective on March 23, 2026. The Company's Common Stock and Warrants are scheduled to begin trading on a reverse stock split-adjusted basis at the opening of Nasdaq on Monday, March 23, 2026. Following the reverse stock split, the Common Stock will continue to trade on Nasdaq under the symbol "AREB" w

    3/19/26 9:30:00 AM ET
    $AREB
    Plastic Products
    Industrials

    Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

    SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan (T-DXd) will be presented at the American Association for Cancer Research Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California. The poster presentation will showcase findings demonstrating that onvansertib enhanced the antitumor activity of T-DXd and reversed resistance in therapy-resistant HER2-low

    3/19/26 7:00:00 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

    FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted a small business waiver of the Prescription Drug User Fee Act (PDUFA) fee of approximately $4.3 million for the New Drug Application (NDA) for D-PLEX₁₀₀, the Company's lead product candidate for th

    3/17/26 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Terns Pharmaceuticals with a new price target

    Leerink Partners initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $58.00

    2/9/26 6:54:14 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Story Brooke

    3 - PolyPid Ltd. (0001611842) (Issuer)

    3/18/26 4:02:57 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Krinsky Itzhak

    3 - PolyPid Ltd. (0001611842) (Issuer)

    3/18/26 4:02:34 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Akselbrad Dikla Czaczkes

    3 - PolyPid Ltd. (0001611842) (Issuer)

    3/18/26 4:02:00 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Relay Therapeutics Inc.

    SCHEDULE 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

    3/19/26 4:07:15 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Planet Labs PBC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Planet Labs PBC (0001836833) (Filer)

    3/19/26 4:05:10 PM ET
    $PL
    Radio And Television Broadcasting And Communications Equipment
    Technology

    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

    8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    3/18/26 5:14:50 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Rent the Runway Appoints Dhiren Fonseca as Executive Chairman

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Rent the Runway, Inc. ("Rent the Runway" or the "Company") (NASDAQ:RENT), the company that is transforming the way women get dressed, today spotlights the appointment of Dhiren Fonseca as Executive Chairman of the Board of Directors, who has served since October 2025. Fonseca is a seasoned business leader with a distinguished track record of scaling high-growth technology and consumer companies. His extensive experience spans private equity, travel, and digital commerce, making him uniquely positioned to guide Rent the Runway as it continues to innovate its platform, deepen its supplier relationships, and explore strategic partnerships. "Dhire

    3/9/26 9:15:00 AM ET
    $RENT
    Other Specialty Stores
    Consumer Discretionary

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Financials

    Live finance-specific insights

    View All

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

    Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuti

    2/25/26 4:07:55 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

    Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an

    2/24/26 4:30:00 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $AREB
    $CDAK
    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    11/29/24 1:20:33 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by JE Cleantech Holdings Limited

    SC 13D/A - JE Cleantech Holdings Ltd (0001905511) (Subject)

    11/25/24 6:13:31 AM ET
    $JCSE
    Miscellaneous manufacturing industries
    Consumer Discretionary